Hualan Biological Engineering, Inc.

On August 26, 2024, news of the suspension of Valling and Valga, the flu vaccines produced by Pasteur, a subsidiary of Sanofi, spread quickly on the Internet. According to netizens, they learned through text messages that a number of medical institutions such as Shanghai Jiahui Medical and Weiernuo have stopped administering Pasteur flu vaccines, including trivalent and quadrivalent vaccines. According to the investigation, the two vaccines have been administered in the Shanghai area for about 10 days. By August 28, the poster reporter had consulted the Shandong Provincial Center for Disease Control and Prevention and learned that the Shandong region had completely stopped vaccinating the vaccine.   On August 27, the customer service of Shanghai Jiahui Medical responded that the hospital had received a notice from the Shanghai Center for Disease Control and Prevention that all hospitals in Shanghai had suspended Pasteur flu vaccination. Customers who have received the vaccine will need to wait for further notice from the authorities.   In Shandong, community health service centers in some cities have also received relevant notices. The reporter learned that Jinan Lixia District, Laiwu District, high-tech district, Licheng District, Huaiyin District and other places, as well as some community health service centers in Dezhou District have begun to vaccinate the flu vaccine, but they received a notice of suspension of Pasteur flu vaccine before and after August 26, and immediately stopped the vaccination.   On the morning of August 28, a staff member of the Xianwen Community Health Service Center in Shunhua Road, a high-tech zone in Jinan City, told reporters: "Pasteur vaccine was gone two days ago, and the previous price was 160 yuan per unit." At present, we have domestic flu vaccines such as Hualan Bio and Guoguang Bio, whose price and effectiveness are not much different from Pasteur vaccine. Staff said they had only been notified of the suspension of Pasteur vaccinations and it was not clear when supplies would resume.   Sanofi told the media on August 27 that flu vaccine products are highly complex. During the ongoing stability study, the company found that the titers of the influenza vaccines Valling and Valga for the 2024-2025 influenza season showed a downward trend. In order to prevent possible impacts, Sanofi has decided to take a precautionary measure and temporarily stop the supply and sale of these vaccines in China.   Children make up a significant proportion of those receiving the two suspended flu vaccines. Valling is suitable for adults and children 36 months and older, while Valga is suitable for people 6 months and older.   Sanofi stressed that the influenza vaccines that have been marketed and circulated this year, Valling and Valga, have gone through strict marketing approval, complied with laws and regulations, national drug standards and statutory requirements, and met the release standards. The company has found no indication or evidence of any impact on the safety and effectiveness of its products. The decision to suspend supply and sales is purely precautionary.   It's worth noting that Pasteur flu vaccines have been recalled in the past. In 2018, Shenzhen Sanofi Pasteur Biological Products Co., Ltd. found that the titer of some batches of influenza virus split vaccine decreased during routine monitoring, and voluntarily recalled the relevant batches of vaccine, with a recall level of level 3.   Vaccine expert Taurina explained: "Those who have received the Pasteur flu vaccine should not be overly worried." He pointed out that each batch of flu vaccine needs to be self-tested and approved by the national drug testing agency before it can be marketed. If a recall occurs after the market, it indicates that the initial self-test and batch issuance are qualified, but subsequent tests find that some indicators are not qualified, and the recall is carried out out of caution.   Shao Yinan, a vaccine science writer, also said Sanofi's recall was a forward-looking recall, a preventive measure taken before a possible titer deficit, rather than a problem with the vaccine itself.

DUBLIN--( BUSINESS WIRE )--The "Hepatitis B Vaccines: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Hepatitis B Vaccines Market to Reach $3.4 Billion by 2027 In the changed post COVID-19 business landscape, the global market for Hepatitis B Vaccines estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027. Combination Vaccines, one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$2.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Mono Vaccines segment is readjusted to a revised 3.1% CAGR for the next 7-year period. The U.S. Market is Estimated at $715.6 Million, While China is Forecast to Grow at 6.5% CAGR The Hepatitis B Vaccines market in the U.S. is estimated at US$715.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$668.6 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 3.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR. Select Competitors (Total 14 Featured) - Beijing Minhai Biotechnology Co., Ltd. Bharat Biotech International Ltd. Binnopharm Group LLC Biokangtai CSL Ltd. Dynavax Technologies Corporation Emergent BioSolutions, Inc. GlaxoSmithKline PLC Hualan Biological Engineering Co., Ltd. Merck & Co., Inc. What's New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and Research Platform Complimentary updates for one year Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights Hepatitis B Vaccines - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned Beijing Minhai Biotechnology Co., Ltd. Bharat Biotech International Ltd. Binnopharm Group LLC Biokangtai CSL Ltd. Dynavax Technologies Corporation Emergent BioSolutions, Inc. GlaxoSmithKline PLC Hualan Biological Engineering Co., Ltd. Merck & Co., Inc. For more information about this report visit https://www.researchandmarkets.com/r/oixc6p

The clinical utility studies planned with the two partners will evaluate the impact of the PDAC assay in enhancing patient outcomes, improving healthcare economics, and delivering benefits for clinicians Biological Dynamics has partnered with QURE and Curta to study the effects of early identification of the cancer in high-risk cohorts with its PDAC assay. (Credit: valelopardo from Pixabay) Biological Dynamics is partnering with QURE Healthcare and Curta to assess its assay in the early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk cohorts. The US-based exosome-isolation technology and early disease detection diagnostic firm said that the clinical utility studies with the two partners will evaluate the impact of its PDAC assay in enhancing patient outcomes, improving healthcare economics, and demonstrating benefits for clinicians. Biological Dynamics announced independent studies to better understand how providers will use its early PDAC detection assay. The test performance and cost related to subsequent patient care and curative interventions that payors evaluate for reimbursement decisions will also be analysed, the firm added. Biological Dynamics CEO and director Paul Billings said: “We believe our technology ventures well beyond the DNA-based sequencing tests available for PDAC to the serial imaging that has been the standard for detecting pancreatic cancer for decades. “We must more fully understand the risks and benefits of early detection methods in all individuals including those at high-risk for pancreatic cancer. “These two studies will add important observations as we evolve to better management of disease risk and sensitive diagnoses.” Curta is engaged in developing models to demonstrate how new medical technologies may affect actual care and results. Biological Dynamics said that the Curta study will examine the potential economic and health effects of early PDAC identification using its PDAC assay. Curta senior partner and CMO Scott Ramsey said: “A blood test is much easier to administer for patients compared to a battery of imaging technologies. It can make clinical flow easier by saving unnecessary tests when the PDAC assay is negative. “Our modelling will characterise the current standard of care for surveillance of patients with high risk for pancreatic cancer.” According to Biological Dynamics, QURE Healthcare measures physicians’ clinical practice patterns to understand how new technology may impact patient care. The Clinical Performance and Value (CPV) patient simulations used in the QURE study will be used in a randomised controlled trial to see whether adopting the PDAC assay would change physician behaviour, the company added.